New scan could spot hidden cancers
NCT ID NCT07458906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new type of PET scan that targets a protein called DLL3, found on some neuroendocrine cancer cells. The goal is to see if this scan can find tumors more accurately than current imaging methods. About 60 adults with suspected or confirmed neuroendocrine cancer will receive a special tracer and then be scanned. The study will also check safety and compare scan results with tumor samples.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLL3-EXPRESSING TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a scan tell who needs more surgery after head and neck cancer?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New drug cocktail aims to shrink Hard-to-Treat gut tumors
- New PET scan targets hidden lung cancer cells
- Brain scan breakthrough: amino acid PET may solve a tricky diagnosis dilemma
- AI-powered PET scans may predict prostate cancer aggressiveness before surgery